Our Stories

To celebrate National Nurses Month 2026, we’re introducing you to our incredible team of Theranostics Infusion Nurses and Clinical Research Nurses.

Bill was the first patient in the world to participate in a clinical trial exploring an experimental radiopharmaceutical therapy for prostate cancer.

2025 was more than a year of milestones; it was a year of impact. A year of bold advances, compassionate care, and lives touched.

With a zest and appreciation for life, at 77 years old, Barbara considered herself the picture of perfect health. But that changed in June of 2025 when she was diagnosed with metastatic HR-/HER2+ breast cancer.

We’re among the first centers in the country to treat patients in the new “pre-chemo” setting. Here’s what we’re learning—and what we’re still working to understand.

Prostate cancer patients whose cancer has spread have a game-changing new option for treatment.

BAMF Health Chief Medical Advisor Dr. Harshad Kulkarni shares his expert perspectives on the field of Theranostics and where it’s headed.

Mike credits the radiopharmaceutical therapy he received at BAMF for shrinking his neuroendocrine tumor and saving his life.

After a decades-long battle with neuroendocrine cancer, Nolan hopes treatment at BAMF Health will stop his cancer in its tracks.